HIV, the virus that causes AIDS, is shown budding out of an immune cell, which the virus infects and uses to replicate.NIH, via Wikimedia Commons
For more than 20 years, powerful drug combinations of antiretroviral drugs have been available to treat people with HIV infection, and these agents have dramatically raised life expectancy for HIV-infected patients from 36 to 49 years of age.
Though combinatorial antiretroviral therapies (CART) reduces viral
loads to undetectable levels in the blood, HIV can hide within the
central nervous system, where it can integrate into the genomes of brain
cells called microglia – the immune cells of the brain.
In the brain, HIV continues to produce viral proteins and damage both
infected and non-infected cells in the brain, boosting the risk for
dementia, addiction and other neurological problems. Everyone with HIV
will experience this, since HIV integrates into the genome and CART has
issues crossing into the brain. The question is: why?
HIV proteins dysregulate dopamine signaling
To answer this, we used a mouse in which we can control the levels of
HIV viral protein in order to probe the link between HIV infection and
neurological disease.
Our lab discovered that an HIV protein, called HIV-1 Tat, reduces the
level of an important protein required for the production of a
dopamine, a neurotransmitter, in the brain.
Dopamine is produced by neurons in the central nervous system and by immune cells in the blood. Using a confocal microscope
to see fine details, my colleagues and I carefully examined the
dopamine producing areas in the brains of mice containing HIV-1 Tat
protein and were surprised to discover that the neurons were alive. But,
many that normally produced dopamine were unable to produce as much. We
also found that an enzyme necessary to make dopamine, called tyrosine
hydroxylase, was no longer detectable in some neurons. This suggests
that the mice can’t make as much dopamine.
When microglial cells secrete the HIV-1 Tat protein, it is able to
enter dopamine neurons and lower their activity so that they produce
less dopamine. That reduces their ability to communicate with other
cells in the brain, which can disrupt the ability to move and reward
related behaviors. Also, low levels of dopamine in an area of the brain
called the substantia nigra is a hallmark of Parkinson’s and
predisposes patients to depression and addiction to drugs like methamphetamine and cocaine.
The results of our research, published in the journal Glia,
reveal how HIV patients are more vulnerable to neurological and
neuropsychiatric conditions that are somehow tied to disrupting dopamine
levels in the brain.
There is clearly more to treating HIV that curbing levels of the
virus in the blood. The medical community needs treatments that reverse
the long-term consequences of HIV infection in the brain.
As antibiotic resistance increases the search for new anti-bacterial treatments becomes more and more important. One way to design anti-bacterials is to find specific biochemical pathways that the bacteria require to survive, and develop drugs that block off these pathways. Some pathways are better targets than others and for Salmonella bacteria it was thought that pathways dealing with nutrient metabolises would be a lost cause. Salmonella lives in the intestine, which hosts a whole variety of different nutrients, so surely preventing the bacteria from using a specific one wouldn’t cause them much undue distress. It’s been found, however, that as they grow and spread in the inflamed intestine the bacteria are heavily reliant on one particular nutrient: fructose-asparagine. The chemical structure of fructose-asparagine, image from the reference. The importance of fructose-asparagine metabolism was originally discovered durin...
For bacteria facing a dose of antibiotics, timing might be the key to evading destruction. In a series of experiments, Princeton researchers found that cells that repaired DNA damaged by antibiotics before resuming growth had a much better chance of surviving treatment. When antibiotics hit a population of bacteria, often a small fraction of "persister" cells survive to pose a threat of recurrent infection. Unlike bacteria with genetic resistance to antibiotics, evidence suggests that persisters stay alive in part by stalling cellular processes targeted by the drugs. In a new study, Princeton researchers examined a class of antibiotics that target bacterial DNA. In bacterial populations, some cells repair damaged DNA before resuming growth, and others resume growth before making repairs. The researchers found that those that make repairs before resuming growth generally are the ones that survive as persisters. The research advances a long-term goal to make ...
Comments
Post a Comment